Jingnan Zhang1, Junyi Wan1, Yihang Li2, Yu Han2, Jiahua Pan3, Fang Fang1, Shiliang Jiang4, Xiangbin Pan1, Gejun Zhang1,*
Congenital Heart Disease, Vol.18, No.2, pp. 219-234, 2023, DOI:10.32604/chd.2023.027562
Abstract Background: The Venus-P valve was the first self-expanding valve used world-wide for transcatheter pulmonary valve replacement (TPVR) in patients with severe pulmonary regurgitation (PR). We intended to report the extended follow-up results from the prospective trial (No. NCT02590679). Methods: A total of 38 patients with severe PR (mean age 24.2 ± 13.2) were included. Follow-up data were obtained after implanted at 1, 6, and 12 months and yearly after. The frame geometry was assessed on post-implant computer tomography (CT) scanning by calculating the non-circularity [circularity ratio (minimum diameter/maximum diameter) < 0.9] and under-expansion [expansion ratio (derived external valve area/nominal external valve area)… More >
Graphic Abstract
Login
Register
